Skip to main content


Fig. 6 | BMC Medicine

Fig. 6

From: The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments

Fig. 6

Sensitivity of risk allocation: the additional 15-year relative prevalence reduction that was possible by allocating treatments (20/1,000 PWID each year) most efficiently to risk groups and vaccinating after treatment in different parameter scenarios. The setting was with 50 % initial chronic HCV prevalence among PWID and a 60 % efficacious vaccine. HCV hepatitis C virus, PWID people who inject drugs

Back to article page